Table 1.

Demographic Descriptions of Included Cohort Studies.

Characteristic	Number of Studies (N=46)	Percentage
Prospective Study Design	28	61
World Health Organization High-burden†	18	39
Tuberculosis Incidence Burden of Country, per 100 thousand persons‡
<50	16	36
50–100	9	19
>100–200	9	19
>200	12	23
World Health Organization Region
African	9	20
Americas	16	33
Eastern Mediterranean	1	2
European	7	15
Southeast Asia	4	9
Western Pacific	9	20
Income Group§
High	14	30
Upper-middle	18	39
Lower-middle	8	17
Low	6	13
HIV Status of Child Reported	23	49
Study Quality Assessment
High	33	72
Moderate	11	24
Low	2	4
Mean Duration of Study Follow-up
<2 years	24	56
2–4 years	13	28
5–7 years	3	11
>7 years	3	7
Cohort size
<1000	20	43
1000–5000	14	30
>5000	12	26
Exposed to Drug Resistant Index Cases
Only Drug-Resistant Index Cases	3	6
Both Drug-Resistant and Susceptible Index Cases	12	26
Only Drug-Susceptible Index Cases	2	4
Preventive Therapy included*	32	70
QuantiFERON or Tuberculin Skin Testing	38	78
Total
Persons-years	429,538	…
Total Individuals Evaluated for Prevalence	137,647	…
Total Individuals Evaluated for Incidence	130,512	…
Median age (IQR)	10.5 (5.7, 15.2)	…
Mean age (SD)	10.3 (5.4)	…

Abbreviations: HIV, human immunodeficiency virus. BCG, bacillus Calmette–Guérin.

Percentages may not total 100% because within-column percentages were rounded to the nearest integer.

^†Studies were designated as being located in a “high-burden” country as classified by the World Health Organization.

^‡Country-level tuberculosis incidence data was collected from World Health Organization databases for each study.

^§Studies were grouped into World Health Organization global regions and World Bank country-level economies (high-income, upper-middle-income, lower-middle-income, and low-income) as of October 2018.

^*This refers to preventive therapy being given to some participants and includes any type of preventive therapy regimen.